The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the accelerating pace of healthcare M&A to drive innovation, GSK has announced a definitive agreement to acquire Nuvalent in an all-cash transaction valued at $10.60 billion. The offer price of $124.00 per share represents a 40% premium over Nuvalent's prior closing price. Concurrently, law firm Halper Sadeh LLC has initiated an investigation into whether the Nuvalent board fulfilled its fiduciary duties to shareholders regarding the deal terms.
This acquisition comes as major pharmaceutical firms face pressure to replenish pipelines ahead of key patent expirations, with GSK aiming to secure Nuvalent’s targeted therapies for ROS1 and ALK-driven lung cancers. Compared to recent sector activity, AstraZeneca recently acquired Fusion Pharmaceuticals for $2.4 billion per market data, underscoring the industry-wide shift toward precision oncology. This marks GSK's largest deal since its acquisition of Affinivax in 2022.
Regarding stock performance, NUVL stood at $123.45 while GSK closed at $52.86 (close June 11, 2026). Traders are now watching for any legal developments that could impact the closing timeline, alongside upcoming U.S. Balance of Trade data which may influence broader market sentiment for healthcare companies with international operations.